AYA Cancer Awareness Week: Patient Support, Multidisciplinary Care Are Key for Management of NETs
Jennifer Chan, MD, underscores the importance of early NET diagnosis in young adult and pediatric patients.
Related Articles
Ide-Cel Displays Potential in Myeloma After Suboptimal Response to Frontline ASCT and Maintenance
Alfred L. Garfall, MD, discusses the role of ide-cel in patients with multiple myeloma following suboptimal responses to upfront auto-HCT.
Dual PD-1/CTLA-4 Inhibition With Cadonilimab Plus Lenvatinib Yields Disease Control in Advanced Endometrial Cancer
Chunyan Lan, MD, PhD, details the efficacy and safety of cadonilimab/lenvatinib in platinum-pretreated advanced endometrial cancer.
Timely G-CSF Administration Is Key for Hematologic AE Management in mPDAC Receiving NALIRIFOX
The association between greater hematologic AEs and increased OS necessitates early receipt of G-CSF after NALIRIFOX infusion for patients with PDAC.
Multidisciplinary BiTE-Associated AE Education Increases the Safety of Outpatient Administration
Educating patients and health care providers about BiTE-associated CRS and ICANS increases comfort levels with giving these agents in outpatient settings.
Real-World Data and CAR T Selection in Second-Line LBCL: Key Insights From ASH 2024
Experts discuss real-world outcomes of lisocabtagene maraleucel (liso-cel) as second-line therapy for relapsed/refractory large B-cell lymphoma (R/R LBCL), including data highlights from the CIMBTR registry…
Dr Paczesny on ST2 as a Biomarker for Acute GVHD Risk Post-Transplant
Sophie Paczesny MD, PhD, discussed the ability of ST2 to predict the risk of developing aGVHD or death following transplant.
Navigating CML Treatment: A Patient-Centered Approach
Jorge Cortes, MD, and Stephen A. Strickland Jr, MD, MSCI,discuss how in the management of chronic myeloid leukemia (CML), clinicians must carefully monitor early treatment…
Emerging Treatment Approaches for HR+/HER2– Early-Stage Breast Cancer
Panelists discuss how emerging treatment strategies, including the use of CDK4/6 inhibitors and personalized risk stratification, are transforming the management of high-risk HR+/HER2– early-stage breast…
Zongertinib Could Alter SOC in HER2-Mutated Advanced NSCLC
John V. Heymach, MD, PhD, discusses updated findings from the phase 1b Beamion LUNG-1 trial of zongertinib in HER2-mutated advanced NSCLC.
Fox Chase Cancer Center Researcher Adria Hasan Honored With Scholar-in-Training Award From American Association for Cancer Research
Fox Chase Cancer Center researcher Adria Hasan honored with scholar-in-training award from American Association for Cancer Research.